Orthopaedic Surgery - Soft-Tissue Tumors

Basics

Soft-tissue tumors arise from the:

Nonepithelial tissues of the musculoskeletal system.

They may originate from:

Fibrous tissue

Skeletal muscle

Tendons

Synovium

Peripheral nerves

Adipose tissue

and other:

Mesenchymal structures.

Classification

Soft-tissue masses include:

Benign neoplasms

Malignant neoplasms

Reactive lesions

and

Normal anatomical variants.

Benign soft-tissue tumors are substantially more common than:

Soft-tissue sarcomas.

Diagnostic Challenge

Distinguishing a benign lesion from a malignant tumor can be:

Difficult.

Some sarcomas may initially appear:

Painless

Slow growing

and relatively innocuous.

Therefore, an indeterminate soft-tissue mass requires a:

Systematic diagnostic approach.

Musculoskeletal Tumor Society Staging

The Musculoskeletal Tumor Society system, commonly called the:

Enneking staging system

classifies both benign and malignant musculoskeletal tumors.

Benign Tumors

Benign tumors are classified as:

Stage 1 – Latent or inactive

Stage 2 – Active

Stage 3 – Aggressive

Stage 1 Benign Tumor

A Stage 1 lesion is generally:

Well contained

Slow growing

and may remain:

Asymptomatic.

Stage 2 Benign Tumor

A Stage 2 lesion demonstrates:

Active growth

but usually remains contained within its:

Anatomic compartment.

Stage 3 Benign Tumor

A Stage 3 lesion behaves:

Locally aggressively

and may extend beyond its:

Normal tissue boundaries.

Although histologically benign, it can cause substantial:

Local destruction.

Malignant Tumors – Enneking System

Malignant tumors are broadly divided into:

Stage I – Low-grade sarcoma

Stage II – High-grade sarcoma

Stage III – Metastatic sarcoma.

The system also considers whether the tumor remains:

Intracompartmental

or has extended:

Extracompartmentally.

AJCC Staging

The:

American Joint Committee on Cancer

also provides staging systems for soft-tissue sarcomas.

Staging incorporates factors such as:

Tumor size

Depth or anatomic site

Histologic grade

Regional nodal disease

and

Distant metastasis.

Older simplified descriptions classified tumors largely according to:

Size

Grade

and presence of:

Metastases.

Epidemiology

Soft-tissue tumors can occur at:

Any age.

The specific tumor types encountered vary substantially according to:

Age group.

Most Common Benign Tumor

The most common soft-tissue tumor overall is:

Lipoma.

Adult Soft-Tissue Sarcomas

In adults, common soft-tissue sarcoma types include:

Liposarcoma

and

Undifferentiated pleomorphic sarcoma.

Pediatric Soft-Tissue Sarcomas

In children and adolescents, important malignant soft-tissue tumors include:

Rhabdomyosarcoma

and

Synovial sarcoma.

Incidence

Soft-tissue masses are:

Common

whereas true soft-tissue sarcomas are:

Rare.

Historically, benign lesions have been estimated to outnumber malignant soft-tissue tumors by approximately:

100:1.

Clinical Importance

Despite the rarity of sarcoma, the clinician must approach an unexplained mass:

Systematically

because inappropriate excision or delayed diagnosis can compromise later:

Definitive treatment.

Sex

Soft-tissue sarcomas have historically been reported somewhat more frequently in:

Males.

Risk Factors

Most patients with soft-tissue sarcoma have:

No identifiable predisposing factor.

Important recognized associations include:

Certain inherited syndromes

Prior radiation

and selected:

Chemical exposures.

Genetics

Most soft-tissue tumors are:

Sporadic

and are not directly inherited.

Neurofibromatosis

An important inherited exception is:

Neurofibromatosis type 1

caused by pathogenic variants involving:

NF1.

Patients have an increased risk of:

Malignant peripheral nerve sheath tumor.

Characteristic Genetic Abnormalities

Some soft-tissue sarcomas are associated with characteristic:

Chromosomal translocations

that can assist diagnosis.

Clear Cell Sarcoma

Clear cell sarcoma is associated with:

t(12;22)

involving characteristic fusion genes.

Extraskeletal Myxoid Chondrosarcoma

Extraskeletal myxoid chondrosarcoma is classically associated with:

t(9;22).

Synovial Sarcoma

Synovial sarcoma is associated with:

t(X;18)

resulting in an:

SS18-SSX fusion.

Alveolar Rhabdomyosarcoma

Alveolar rhabdomyosarcoma commonly demonstrates:

t(2;13)

or related rearrangements involving:

PAX and FOXO1 genes.

Myxoid Liposarcoma

Myxoid liposarcoma is characteristically associated with:

t(12;16).

Alveolar Soft-Part Sarcoma

Alveolar soft-part sarcoma has a characteristic:

X;17 translocation

producing an:

ASPSCR1-TFE3 fusion.

Extraskeletal Ewing Sarcoma

Extraskeletal Ewing sarcoma commonly demonstrates:

t(11;22)

with an:

EWSR1-FLI1 fusion.

Etiology

For most soft-tissue tumors, the exact cause is:

Unknown.

Trauma

Trauma generally does not cause sarcoma.

However, muscle injury may lead to reactive lesions such as:

Myositis ossificans

which can mimic a neoplasm clinically or radiographically.

Chemical Exposure

Exposure to certain industrial chemicals has been associated with an increased risk of:

Soft-tissue sarcoma

in selected populations.

Diagnosis

Evaluation begins with:

History

Physical examination

and appropriate:

Imaging.

Signs and Symptoms

The usual presentation is a:

Soft-tissue mass.

It may be:

Painless

or

Painful.

Growth

The lesion may remain stable or may progressively:

Increase in size.

A progressively enlarging mass should raise concern for:

Malignancy.

Features Concerning for Sarcoma

Particularly concerning findings include:

Increasing size

Deep location

Large size

Fixation to surrounding tissues

and unexplained:

Pain.

Physical Examination

Document:

Size

Location

Depth

Mobility

and the relationship of the mass to surrounding:

Skin

Muscle

Bone

Nerves

and

Vessels.

Mobility

A freely mobile superficial mass is more often:

Benign

although mobility alone cannot reliably exclude:

Malignancy.

A fixed mass may suggest involvement of:

Deep fascia

Muscle

Bone

or other adjacent structures.

Regional Lymph Nodes

Examine the relevant:

Regional lymph-node basins

for:

Lymphadenopathy.

Most adult soft-tissue sarcomas spread primarily through the:

Bloodstream

rather than lymphatics, but certain histologic types have a greater propensity for:

Nodal metastasis.

Laboratory Tests

There are generally:

No specific routine laboratory tests

that diagnose a soft-tissue tumor.

Laboratory evaluation is guided by:

Clinical context

and suspected diagnosis.

Imaging

Plain Radiographs

Plain radiography is frequently the first imaging study.

Although most soft-tissue tumors are not diagnosed from radiographs alone, several findings can be highly informative.

Phleboliths

Calcified venous thrombi called:

Phleboliths

may be seen in:

Venous malformations or hemangioma-type vascular lesions.

They are highly suggestive when present.

Lipoma

Deep lipomas may occasionally appear as a relatively:

Radiolucent oval soft-tissue mass

because of their fat content.

Myositis Ossificans

Myositis ossificans typically develops a characteristic:

Zonal pattern of mineralization.

The lesion becomes more heavily ossified at the:

Periphery

while remaining relatively lucent toward the:

Center.

This pattern helps distinguish it from some malignant lesions.

Synovial Sarcoma

Approximately:

20–30%

of synovial sarcomas may contain:

Scattered calcifications.

Ultrasound

Ultrasound can help distinguish a:

Cystic

from a:

Solid lesion.

It can also evaluate:

Vascularity

and guide:

Aspiration or biopsy.

MRI

MRI is the principal imaging modality for characterization of most:

Soft-tissue masses.

It provides excellent definition of:

Tumor size

Depth

Anatomic compartment

Relationship to fascia

Neurovascular structures

and surrounding:

Muscle and bone.

Determinate Mass

A mass is considered:

Determinate

when imaging features are sufficiently characteristic to establish a confident diagnosis.

Examples include some:

Simple lipomas

and

Ganglion cysts.

Indeterminate Mass

A mass is considered:

Indeterminate

when imaging cannot establish a specific diagnosis with adequate certainty.

Sarcomas and MRI

Soft-tissue sarcomas generally appear as:

Indeterminate masses.

However, many benign tumors can also be:

Indeterminate.

Therefore, an indeterminate lesion should not automatically be assumed to be:

Malignant

or

Benign.

MRI Features Suggesting Aggressive Disease

Features that may increase concern include:

Large size

Deep fascial location

Heterogeneous signal

Necrosis

Peritumoral edema

and invasion of:

Adjacent structures.

None of these findings alone is completely diagnostic.

Biopsy

An indeterminate soft-tissue mass that cannot be confidently characterized may require:

Biopsy.

Biopsy Planning

Biopsy should ideally be planned by the:

Orthopaedic oncology or sarcoma team

that would perform definitive treatment.

The biopsy tract should be positioned so that it can later be:

Completely excised

during tumor resection.

Core Needle Biopsy

Image-guided:

Core needle biopsy

is commonly preferred because it provides tissue architecture while minimizing:

Contamination of surrounding tissues.

Pathological Findings

Histologic evaluation of soft-tissue tumors can be:

Challenging.

Specialist Pathology

Interpretation is best performed by a pathologist experienced in:

Musculoskeletal and soft-tissue tumors.

Incorrect classification or grading can alter:

Treatment

and

Prognosis.

Molecular Testing

Selected tumors may require:

Immunohistochemistry

Cytogenetics

or

Molecular testing

to confirm the diagnosis.

Differential Diagnosis

The differential includes tumors arising primarily from:

Bone

with extension into the:

Soft tissues.

Intramedullary Bone Tumor

A primary intramedullary bone tumor may break through the:

Cortex

and create a large:

Soft-tissue component.

Surface Bone Tumor

A tumor arising from the surface of bone may also present clinically as a:

Soft-tissue mass.

Imaging should therefore establish whether the lesion originates from:

Soft tissue

or

Bone.

Treatment

Treatment depends on whether the lesion is:

Benign

Malignant

or

Reactive.

Observation

Observation is appropriate for selected:

Asymptomatic benign lesions

when the diagnosis is confidently established.

Examples include some:

Lipomas

and

Ganglion cysts.

Requirement for Observation

Observation should only be chosen when the clinician is sufficiently certain:

What the lesion is.

An unidentified mass should not simply be labeled:

“Probably benign.”

Indeterminate Lesions

If the diagnosis remains uncertain, further:

Imaging

or

Biopsy

is generally appropriate before definitive treatment.

Activity

Routine activity restriction is usually unnecessary solely because a patient has a:

Soft-tissue tumor.

Unlike many bone tumors, there is generally no direct risk of:

Pathological fracture

from the soft-tissue mass itself.

Restrictions may still be appropriate if the lesion causes:

Pain

Neurologic compromise

or other functional limitations.

Physical Therapy

Physical therapy is often useful:

Postoperatively

to restore:

Range of motion

Strength

and

Function.

Medication

Chemotherapy

Cytotoxic chemotherapy is used for selected:

Soft-tissue sarcomas.

Its role depends strongly on:

Histologic subtype

Stage

Age

and overall:

Patient fitness.

Chemosensitive Tumors

Sarcomas such as:

Rhabdomyosarcoma

and

Ewing sarcoma

are substantially more chemotherapy-sensitive than many common adult:

Soft-tissue sarcomas.

Surgery

Surgery is the cornerstone of local treatment for many soft-tissue tumors.

The required margin depends on:

Biologic behavior

and

Malignancy grade.

Benign Tumors

Benign lesions may be removed with:

Intralesional

or

Marginal excision

depending on the tumor type and recurrence risk.

Malignant Tumors

Soft-tissue sarcomas generally require:

Wide excision

with a cuff of:

Normal tissue

around the tumor.

The goal is an:

Microscopically negative margin.

Radical Excision

A radical margin removes the entire:

Anatomic compartment

containing the tumor.

This is now less commonly required because modern treatment often combines:

Limb-sparing surgery

with

Radiation therapy.

Limb-Sparing Surgery

The great majority of extremity sarcomas can now be treated with:

Limb-sparing surgery.

Historical series report rates approaching:

95%.

Requirements for Limb Salvage

Successful limb salvage requires:

Complete tumor removal with negative margins

A functional extremity after reconstruction

and

Acceptable wound healing

so that additional treatment such as:

Radiation

or

Chemotherapy

is not compromised.

Major Nerve or Vessel Involvement

Extensive involvement of:

Major nerves

or

Major blood vessels

may make limb salvage difficult.

In selected cases, vascular reconstruction or nerve sacrifice may still permit limb preservation, while other cases may require:

Amputation.

Radiation Therapy

Radiation therapy is frequently combined with surgery for:

Intermediate- or high-grade soft-tissue sarcomas

to reduce the risk of:

Local recurrence.

Preoperative Radiation

Radiation given before surgery generally treats a:

Smaller field

and may reduce certain long-term tissue effects, but it is associated with a higher risk of:

Early wound complications.

Postoperative Radiation

Postoperative radiation may reduce the risk of:

Wound-healing problems

relative to preoperative treatment but usually requires a larger field and may produce greater long-term:

Fibrosis

Edema

and

Joint stiffness.

Prognosis

Prognosis depends primarily on:

Histologic grade

Tumor size

Depth

Anatomic site

Margin status

and presence of:

Metastatic disease.

Local Recurrence

With appropriate multidisciplinary treatment, local recurrence should generally be:

Uncommon.

Historical rates are approximately:

5–10%.

Pulmonary Metastases

The lungs are the most common site of distant spread for many:

Extremity soft-tissue sarcomas.

In selected high-risk tumors, the risk of pulmonary metastasis may approach:

50%.

High-Risk Tumors

Large:

High-grade

and

Deep tumors

have the greatest risk of:

Metastatic spread.

Tumor Size

Increasing tumor size is associated with a progressively worse:

Prognosis.

Older staging descriptions often emphasized size categories such as:

5–10 cm

10–15 cm

and

Greater than 15 cm.

Complications

Wound Complications

When surgery and radiation are combined, complications such as:

Infection

and

Wound breakdown

may occur.

Historical rates have ranged from approximately:

10–30%.

Local Recurrence

Local recurrence occurs in approximately:

5–10%

of appropriately treated patients, although risk varies according to:

Tumor biology

Margin status

and treatment.

Diagnostic Error

Incorrect histologic diagnosis is an important potential complication because:

Soft-tissue pathology is complex.

Expert pathological review is particularly valuable when the diagnosis is:

Unusual

or treatment would be substantially altered by subtype.

Functional Complications

Treatment may also result in:

Muscle weakness

Joint stiffness

Lymphedema

Nerve deficits

and limitations in:

Limb function.

Patient Monitoring

Surveillance is directed toward detecting:

Local recurrence

and

Distant metastasis.

Local Surveillance

MRI with contrast is often used to evaluate the:

Surgical bed

when local imaging is required.

Historical Surveillance Schedule

Older protocols commonly obtained local MRI approximately:

Every 3 months for the first 2 years

then:

Every 6 months for another year

followed by:

Annual imaging through approximately 5 years.

Modern schedules are individualized according to:

Tumor grade

Size

Histology

and

Recurrence risk.

Pulmonary Surveillance

Because the lungs are the most common metastatic site, follow-up usually includes:

Chest imaging.

Historical Chest Surveillance

Older protocols often used:

Chest CT every 3 months for approximately 3 years

followed by less frequent:

Chest CT or radiography

for prolonged surveillance.

Modern follow-up intervals are tailored according to:

Sarcoma subtype

Stage

and institutional protocols.

Long-Term Follow-Up

Some sarcomas can recur or metastasize:

Years after initial treatment.

Long-term surveillance may therefore be appropriate, particularly for:

Higher-risk histologies.

Key Principle

Soft-tissue tumors arise from mesenchymal tissues such as fat, muscle, fibrous tissue, tendons, synovium, and peripheral nerves and may be:

Benign, malignant, reactive, or normal variants.

Benign tumors greatly outnumber:

Soft-tissue sarcomas, but an enlarging, deep, fixed, or otherwise indeterminate mass should never be assumed to be harmless.

MRI is the principal study for defining:

Tumor size, depth, compartment, and relationship to surrounding structures, but many sarcomas and benign tumors remain indeterminate on imaging and therefore require:

Properly planned biopsy.

Treatment of sarcoma is multidisciplinary and usually combines:

Wide surgical excision with negative margins, selective radiation therapy, and subtype-specific systemic treatment.

Careful biopsy planning, expert pathology, appropriate oncologic surgery, and long-term surveillance are essential for minimizing:

Local recurrence, metastatic spread, and avoidable loss of limb function.